Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review.
Peter J GoadsbyCalvin ChanMaría Dolores Villar-MartínezPeter J GoadsbyPublished in: Headache (2020)
Current available therapies have either been nonspecific or had important limitations, including in patients with cardiovascular risk factors. Phase III clinical trials of lasmiditan, rimegepant and ubrogepant all met their primary endpoints, so the options for migraine-targeted acute therapy will likely soon increase.
Keyphrases
- phase iii
- cardiovascular risk factors
- clinical trial
- liver failure
- respiratory failure
- open label
- cancer therapy
- drug induced
- phase ii
- metabolic syndrome
- aortic dissection
- case report
- tyrosine kinase
- stem cells
- drug delivery
- placebo controlled
- extracorporeal membrane oxygenation
- mesenchymal stem cells
- intensive care unit
- study protocol